Method for detecting premature senescence in tumor cells and a kit for detecting premature senescence in tumor cells
AssigneeKorea Institute of Radiological & Medical Sciences
InventorsJae-Seon LEE, Kee-Ho LEE, Hae-Ok BYUN, Na-Kyung HAN
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for detecting senescence in tumor cells and a kit for detecting senescence in tumor cells. eEF1A1 and CD markers are provided, wherein changes in the levels of the markers are correlated with premature senescence of tumor cells.
Claims24
A method for detecting premature senescence in tumor cells, comprising:
- (a) detecting a level of a target protein in a tumor sample, wherein the protein is one or more selected from the group consisting of eukaryotic elongation factor 1 alpha 1 (eEF1A1) and cathepsin D (CD);
- and
- (b) comparing a level of the target protein of Step (a) and a level of the same protein in a control tumor cell sample to determine one or more of decrease of eEF1A1 level and increase of CD level in the tumor sample.
A method for detecting a premature senescence state of tumor cells in a human subject, comprising:
- (a) detecting a level of a target protein in a tumor sample obtained from the human subject, wherein the protein is one or more selected from the group consisting of eukaryotic elongation factor 1 alpha 1 (eEF1A1) and cathepsin D (CD);
- and
- (b) comparing a level of the target protein of Step (a) and a level of the same protein in a control tumor cell sample to determine one or more of decrease of eEF1A1 level and increase of CD level in the tumor sample.
A method for the diagnosis or prognosis of a premalignant or malignant state of tumor cells in a human subject, comprising:
- (a) detecting a level of a target protein in a tumor sample obtained from the human subject, wherein the protein is one or more selected from the group consisting of eukaryotic elongation factor 1 alpha 1 (eEF1A1) and cathepsin D (CD);
- and
- (b) comparing a level of the target protein of Step (a) and a level of the same protein in a control tumor cell sample to determine one or more of decrease of eEF1A1 level and increase of CD level in the tumor sample.
A method of screening for a premature senescence-inducing agent in a tumor cell, comprising:
- (a) collecting a first tumor cell sample before exposing to a candidate premature senescence-inducing agent;
- (b) collecting a second tumor cell sample after exposing to a candidate premature senescence-inducing agent;
- (c) detecting levels of one or more of CD and eEF1A1 in the first and second samples;
- (d) determining whether a level of CD increases and/or whether a level of eEF1A1 decreases;
- and
- (e) identifying a candidate agent exhibiting one or more of an increased CD level and a decreased eEF 1A1 level, as a premature senescence-inducing agent.
A method of screening a potential candidate of cancer therapy in a human subject, the method comprising:
- (a) collecting a first tumor cell sample before exposing to a candidate premature senescence-inducing agent;
- (b) collecting a second tumor cell sample after exposing to a candidate premature senescence-inducing agent;
- (c) detecting levels of one or more of CD and eEF1A1 in the first and second samples;
- (d) determining whether a level of CD increases and/or whether a level of eEF1A1 decreases;
- and
- (e) identifying a potential cancer therapy agent exhibiting one or more of an increased CD level and a decreased eEF1A1 level, as a premature senescence-inducing agent.
A kit for detecting premature senescence in tumor cells, comprising antibodies directed against eEF1A1 and antibodies directed against CD.
Dependencies are inferred from the claim text.